Cancer and Metastasis Reviews

, Volume 27, Issue 3, pp 415–434

Clinical biomarkers of angiogenesis inhibition

  • Aaron P. Brown
  • Deborah E. Citrin
  • Kevin A. Camphausen
Article

DOI: 10.1007/s10555-008-9143-x

Cite this article as:
Brown, A.P., Citrin, D.E. & Camphausen, K.A. Cancer Metastasis Rev (2008) 27: 415. doi:10.1007/s10555-008-9143-x

Abstract

Introduction

An expanding understanding of the importance of angiogenesis in oncology and the development of numerous angiogenesis inhibitors are driving the search for biomarkers of angiogenesis. We review currently available candidate biomarkers and surrogate markers of anti-angiogenic agent effect.

Discussion

A number of invasive, minimally invasive, and non-invasive tools are described with their potential benefits and limitations. Diverse markers can evaluate tumor tissue or biological fluids, or specialized imaging modalities.

Conclusions

The inclusion of these markers into clinical trials may provide insight into appropriate dosing for desired biological effects, appropriate timing of additional therapy, prediction of individual response to an agent, insight into the interaction of chemotherapy and radiation following exposure to these agents, and perhaps most importantly, a better understanding of the complex nature of angiogenesis in human tumors. While many markers have potential for clinical use, it is not yet clear which marker or combination of markers will prove most useful.

Keywords

CancerAngiogenesisBiomarkerImaging

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Aaron P. Brown
    • 1
  • Deborah E. Citrin
    • 2
  • Kevin A. Camphausen
    • 3
  1. 1.National Institutes of HealthBethesdaUSA
  2. 2.Radiation Oncology Branch, National Cancer InstituteBethesdaUSA
  3. 3.Radiation Oncology Branch, National Cancer InstituteBethesdaUSA